NCT01002222 - Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c) | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions

Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia

Interventions

DRUG

MCS-2

15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.

Trial Locations (1)

90095

David Geffen School of Medicine at UCLA, Los Angeles